Shots:
- Chinese NMPA has approved the P-III trial of mesutoclax (ICP-248) in combination with azacitidine vs venetoclax with azacitidine in elderly or unfit pts with treatment-naïve acute myeloid leukemia (TN AML)
- At ASCO’26, the combination achieved an 81.8% composite CR rate in evaluable TN AML pts (as of Apr 13, 2026), with 86.5% of responders MRD-negative & 83% of cCR responders achieving remission in Cycle 1. MTD was not reached, 30 & 60-day mortality were 0%, & 6mos. OS was 90.5% at the recommended dose
- Mesutoclax is an oral, selective BCL2 inhibitor that exerts anti-tumor activity by restoring apoptosis in cancer cells
Ref: Globenewswire | Image: InnoCare | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
